Literature DB >> 2084238

C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study.

E J ter Borg1, G Horst, P C Limburg, M H van Rijswijk, C G Kallenberg.   

Abstract

We prospectively studied the value of measuring C-reactive protein (CRP) levels in patients with systemic lupus erythematosus (SLE) to distinguish between disease exacerbation and infection. During a 2 year followup of 71 lupus patients, 38 episodes of disease exacerbation and 36 episodes of infection could be analyzed. Plasma samples were obtained at least once a month. CRP levels were increased (greater than 6 mg/l) during 25 of the 38 exacerbations and during 32 of the 36 infections. Median CRP levels during infection (60 mg/l; range 1-400) were higher than during disease exacerbation (16.5 mg/l; range 1-375) (p less than 0.05). Levels of CRP rose prior to the exacerbation (p less than or equal to 0.01) and fell afterwards (p less than or equal to 0.01). During exacerbations accompanied by serositis, median levels of CRP (76 mg/l; range 2-375) were higher than during exacerbations without serositis (16 mg/l; range 1-53) (p less than 0.02). CRP levels exceeding 60 mg/l during exacerbations without serositis indicated infection in all cases. Thus, measurement of CRP in SLE is valuable to distinguish between infection and exacerbation only in the absence of serositis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2084238

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  25 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity.

Authors:  Valentin Sebastian Schäfer; Katharina Weiß; Andreas Krause; Wolfgang Andreas Schmidt
Journal:  Clin Rheumatol       Date:  2018-04-14       Impact factor: 2.980

3.  New-onset systemic lupus erythematosus in a long-term hemodialysis patient with acute pleuritis and pneumonitis.

Authors:  Hiroto Hiyamuta; Shunsuke Yamada; Ryusuke Yotsueda; Shoko Hasegawa; Toshiaki Nakano; Masatomo Taniguchi; Hiroshi Tsukamoto; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  CEN Case Rep       Date:  2014-11-07

4.  The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever.

Authors:  E Littlejohn; W Marder; E Lewis; S Francis; J Jackish; W J McCune; E C Somers
Journal:  Lupus       Date:  2018-03-16       Impact factor: 2.911

5.  Assessment of lupus: where are we now?

Authors:  E Hay; C Gordon; P Emery
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

Review 6.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

7.  Significantly higher percentage of circulating CD27(high) plasma cells in systemic lupus erythematosus patients with infection than with disease flare-up.

Authors:  Deng-Ho Yang; Deh-Ming Chang; Jenn-Haung Lai; Fu-Huang Lin; Chen-Hung Chen
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

8.  Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction.

Authors:  M Bijl; H Bootsma; Y Van Der Geld; P C Limburg; C G M Kallenberg; M H Van Rijswijk
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 9.  Lupus activity in pregnancy.

Authors:  Megan E B Clowse
Journal:  Rheum Dis Clin North Am       Date:  2007-05       Impact factor: 2.670

Review 10.  C-reactive protein and the biology of disease.

Authors:  Waliza Ansar; Shyamasree Ghosh
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.